Showing results (81-90 of 161) with videos related to
Sort By:
Pageof 17
Medical Sciences (Basel, Switzerland)|April 24, 2026
Cognitive and Psychosocial Burden of Childhood Cancer Survivors in Greece: A Case-Control StudyKalliopi Mavrea, Katerina Katsibardi, Kleoniki Roka, et al.British Journal of Haematology|September 13, 2014
Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non-transfusion-dependent thalassaemiaAli T Taher, John B Porter, Vip Viprakasit, et al.Health and Quality of Life Outcomes|November 21, 2018
Patient-reported outcomes from a randomized phase II study of the deferasirox film-coated tablet in patients with transfusion-dependent anemiasAli T Taher, Raffaella Origa, Silverio Perrotta, et al.European Journal of Haematology|January 28, 2014
Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasiroxAli T Taher, John B Porter, Vip Viprakasit, et al.Journal of Hematology & Oncology|January 1, 2015
Microrna expression signatures predict patient progression and disease outcome in pediatric embryonal central nervous system neoplasmsMaria Braoudaki, George I Lambrou, Krinio Giannikou, et al.Dentistry Journal|January 24, 2025
Sporadic Burkitt Lymphoma First Presenting as Painful Gingival Swellings and Tooth Hypermobility: A Life-Saving ReferralErofili Papadopoulou, Maria Kouri, Dimitrios Velonis, et al.British Journal of Haematology|March 14, 2022
Immune response and adverse events after vaccination against SARS-CoV-2 in adult patients with transfusion-dependent thalassaemiaPolyxeni Delaporta, Evangelos Terpos, Elena E Solomou, et al.American Journal of Hematology|February 1, 2017
New film-coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower-risk MDS: Results of the randomized, phase II ECLIPSE studyAli T Taher, Raffaella Origa, Silverio Perrotta, et al.Blood|May 17, 2012
Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled studyAli T Taher, John Porter, Vip Viprakasit, et al.In Vivo (Athens, Greece)|September 3, 2020
A Case Series of BCOR Sarcomas With a New Splice Variant of BCOR/CCNB3 Fusion GeneAnastasios Kyriazoglou, Natalia Tourkantoni, Michalis Liontos, et al.Pageof 17